• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DESVENLAFAXINE Drug Record

  • Summary
  • Interactions
  • Claims
  • DESVENLAFAXINE chembl:CHEMBL1118 Approved

    Alternate Names:

    PRISTIQ
    DESVENLAFAXINE
    ODV
    KHEDEZLA
    O-DESMETHYLVENLAFAXINE
    O-DESMETHYLVENLAFAXINE (ODV)
    4-[2-(DIMETHYLAMINO)-1-(1-HYDROXYCYCLOHEXYL)ETHYL]PHENOL
    WY-45233
    1-[2-(DIMETHYLAMINO)-1-(4-HYDROXYPHENYL)ETHYL]CYCLOHEXANOL
    PRISTIQ®
    chemidplus:93413-62-8
    rxcui:734064
    drugbank:06700
    chembl:CHEMBL1118
    pubchem.compound:125017

    Drug Info:

    FDA Approval approved
    Drug Class Small molecule
    Drug Indications for treatment of menopausal symptoms,antidepressant
    Year of Approval 2008
    Drug Class antidepressant
    (3 More Sources)

    Publications:

    Reddy et al., 2010, Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician., Curr Med Res Opin
    Liebowitz et al., 2010, Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder:a systematic review of clinical trials., Prim Care Companion J Clin Psychiatry
    Perry et al., 2009, Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder., Clin Ther
    Mason et al., 2007, Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter., J. Pharmacol. Exp. Ther.
    Deecher et al., 2006, Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor., J. Pharmacol. Exp. Ther.
    Kamath et al., 2008, Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence., Expert Rev Neurother
    Montané Jaime LK et al., 2018, Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder., Pharmacogenomics
  • DESVENLAFAXINE   SLC6A2

    Interaction Score: 2.54

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name Pristiq

    PMIDs:
    19919295 20944767 19698900 17673606 16675639 19086875


    Sources:
    TdgClinicalTrial TEND

  • DESVENLAFAXINE   SLC6A4

    Interaction Score: 1.9

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Pristiq
    Novel drug target Established target

    PMIDs:
    19919295 20944767 19698900 17673606 16675639 19086875


    Sources:
    TdgClinicalTrial TEND

  • DESVENLAFAXINE   NAT1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Norepinephrine transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • DESVENLAFAXINE   CYP2D6

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29327975


    Sources:
    PharmGKB FDA

  • DESVENLAFAXINE   HTT

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin transporter inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TEND: DESVENLAFAXINE

    • Version: 01-August-2011

    Alternate Names:
    DESVENLAFAXINE Primary Drug Name

    Drug Info:
    Drug Class antidepressant
    Year of Approval 2008

    Publications:

  • TdgClinicalTrial: DESVENLAFAXINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of menopausal symptoms,antidepressant
    Drug Class Small molecule
    FDA Approval approved

    Publications:

  • PharmGKB: desvenlafaxine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Montané Jaime LK et al., 2018, Impact of CYP2D6 on venlafaxine metabolism in Trinidadian patients with major depressive disorder., Pharmacogenomics

  • TTD: Desvenlafaxine

    • Version: 2020.06.01

    Alternate Names:
    D0O3FG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1118

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1118

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Desvenlafaxine

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21